Ciraparantag

DB15199InvestigationalSmall molecule

Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).

Formula / weight: C₂₂H₄₈N₁₂O₂ · 512.708 g/mol (avg)
Code names: PER-977

Resolves to

Compound

UNIIU2R67KV65QCAS1438492-26-2ChEMBLCHEMBL3544919

Structure

InChIKeyHRDUUSCYRPOMSO-ROUUACIJSA-NSMILESN[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1

What you can answer from here — as of April 23, 2025

6Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Ciraparantag, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account